First Trade Date for Chiron Corp.
| Company Name | First Trade Date (yyyy-mm-dd) |
| Chiron Corp. | 1983-08-02 |
| Company Name | Symbol |
| Chiron Corp. | CHIR |
| History and Business of Company (this information may include date of incorporation) | |
|
Chiron Corp. (CHIR) is a biotechnology company that focuses on the development, manufacture and marketing of biopharmaceuticals with an emphasis on cancer and infection, vaccines and blood testing products. Switzerland-based Novartis, a global drug and chemical producer, has about a 44% interest in Chiron. The acquisition of PathoGenesis Corp. in September 2000 expanded the company's biopharmaceuticals business and its research initiatives in anti-infectives. Biopharmaceuticals accounted for about 38% of total revenues in 1999, vaccines for 33%, blood testing products for 15%, and other operations for 14%. Revenues in 1999 broke down geographically as follows: U.S. 44%, Germany 22%, Switzerland 7%, Italy 8%, and all other countries 19%. The company's leading therapeutic product is Proleukin. This drug is a recombinant form of interleukin-2, a protein produced by the body to stimulate the production of infection-fighting white blood cells. Proleukin is currently being sold to treat kidney cancer and melanoma. CHIR continues to pursue the use of Proleukin for additional indications, including human immunodeficiency virus (HIV). Other products include recombinant human platelet-derived growth factor (PDGF), the active ingredient in Johnson & Johnson's Regranex drug for diabetic foot ulcers; and Betaseron, a treatment for relapsing/remitting multiple sclerosis that Chiron manufactures for sale by Berlex Laboratories. Chiron Vaccines offers traditional pediatric and flu vaccines through subsidiaries in Italy, Germany, and other foreign countries. Vaccines are marketed for meningitis, flu, measles, rubella, hepatitis A & B, polio, tuberculosis, cholera, rabies and various other ailments. CHIR also has developed an adjuvanted flu vaccine sold currently sold in Italy, and has commenced sales of Menjugate, its conjugate vaccine against meningococcal to the U.K. Chiron also receives royalties from Merck & Co., Inc. on their sales of hepatitis B vaccines. Blood testing operations are conducted through a joint venture with the Ortho division of Johnson & Johnson and an alliance with Gen-Probe. The Ortho joint venture produces diagnostic tests for hepatitis and HIV, with Chiron performing certain research and antigen manufacturing functions and Ortho producing and marketing assays and instrument systems. Chiron's collaboration with Gen- Probe is developing products that use nucleic acid testing technology to screen blood and plasma for viral infections. INCORPORATED in Delaware in February 1987, and Feb. 6, 1987, merged share-for-share a predecessor company with the same name. Predecessor was incorporated in California May 28, 1981. OFFICE- 4560 Horton St., Emeryville, CA 94608 (Tel.: 510-655-8730). Fax - 510-655-9910. WEBSITE-http://www.chiron.com. | |
IMPORTANT DISCLAIMER: By reading any of the material on this website you agree to our DISCLAIMER: The Magi Society, Magi Astrologers Worldwide Corporation make no claims whatsoever concerning the validity of the information provided herein, and will not be held liable for any use thereof. No information or opinion expressed here is a solicitation to buy or sell securities, bonds, real estate, commodities, options, futures or any financial instruments whatsoever.
Back to first trade date main page
Back to financial astrology page
© 1999-2004 by Magi Astrologers Worldwide Corporation. All Rights Reserved.